Amarin Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Amarin Stock Forecast and Price Target
The average price target for Amarin's stock set by recognized analysts recently is $1.00, which would result in a potential upside of approximately 16.28% if it reached this mark. The estimation is based on a high estimate of $1.25 and a low estimate of $1.00. Even if not interested in AMRN stock, you may want to be aware of its competitors.
16.28% Upside
Amarin Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Amarin's Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that Amarin's Fair Value will increase in the upcoming year, reaching $0.91. This would represent an increase of 100.00%. Over the next seven years, experts predict that Amarin's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$733.51 | Buy/Sell | $636.99 | 14.18% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£119.88 | Buy/Sell | £165.99 | 35.15% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.40 | Buy/Sell | $32.87 | 20.08% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.98 | Buy/Sell | $303.65 | 17.51% |
Amarin Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Amarin's Revenue has decreased by 50.02%, going from $614.06M to $306.91M. 4 analysts predict Amarin's Revenue will decrease by 27.64% in the next year, reaching $222.09M. Over the next eight years, experts predict that Amarin's Revenue will grow at a rate of 150.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.23€ | Buy/Sell | 102.80€ | 19.48% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.85 | Buy/Sell | $58.15 | 21.52% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.42 | Buy/Sell | $87.82 | 22.29% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.40€ | Buy/Sell | 45.15€ | 9.49% |
| MTNB Stock Forecast | Matinas BioPharma Holdings | Buy |
7
|
$0.18 | Buy/Sell | $0.65 | 455.56% |
| CDXI Stock Forecast | Cardax | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
Amarin EBITDA Forecast for 2023 - 2025 - 2030
Amarin's EBITDA has grown in the last three years, jumping from $-17.62M to $-53.65M – an increase of 204.48%. In the next year, analysts predict that EBITDA will reach $-71.87M – an increase of 33.96%. For the next seven years, the forecast is for EBITDA to grow by 1472.33%.
Amarin EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Amarin's EBIT has increased by 188.00%, going from $-19.66M to $-56.62M. According to the 3 analysts polled, in the next year, Amarin's EBIT will fall by 17.38%, reaching $-46.78M. By 2030, professionals believe that Amarin's EBIT will have decreased by 779.97%, falling to $385.00M.
Amarin EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Amarin's EPS has seen an increase, rising from $-0.05 to $0.00. This represents a growth of 100.00%. Analysts predict that Amarin's EPS will increase in the upcoming year, reaching $-0.11. This would represent an increase of 100.00%. Over the next seven years, experts predict that Amarin's EPS will grow at a rate of 100.00%.
.jpg)